

APPENDIX

Table A1: List of Antibiotics Used to Construct Study's Dependent Variable

Description	Prescription		
Aminoglycosides	amikacin	kanamycin	tobramycin
	gentamicin	streptomycin	
Aminopenicillins	amoxicillin	ampicillin	
Antipseudomonal penicillins	piperacillin	ticarcillin	
Beta-lactamase inhibitors	amoxicillin-clavulanate	piperacillin-tazobactam	ticarcillin-clavulanate
	ampicillin-sulbactam		
First-generation cephalosporins	cefadroxil	cefazolin	cephalexin
Fourth-generation cephalosporins	cefepime		
Ketolides	telithromycin		
Lincomycin derivatives	clindamycin	lincomycin	
Macrolides	azithromycin	erythromycin	erythromycin
	clarithromycin	erythromycin ethylsuccinate	lactobionate erythromycin stearate
Miscellaneous antibiotics	aztreonam	daptomycin	metronidazole
	chloramphenicol	erythromycin-sulfisoxazole	vancomycin
	dalfopristin-quinupristin	linezolid	
Natural penicillins	penicillin G	penicillin G procaine	penicillin V
	benzathine-procaine	penicillin G sodium	potassium penicillin G
	penicillin G potassium		benzathine oxacillin
Penicillinase resistant penicillins	dicloxacillin	nafcillin	
Quinolones	ciprofloxacin	levofloxacin	norfloxacin
	gatifloxacin	lomefloxacin	ofloxacin
	gemifloxacin	moxifloxacin	sparfloxacin
Rifamycin derivatives	rifampin		
Second generation cephalosporin	cefaclor	cefoxitin	cefuroxime
Sulfonamides	cefotetan	cefprozil	loracarbef
	sulfadiazine	sulfisoxazole	
	sulfamethoxazole-trimethoprim		
Tetracyclines	doxycycline	minocycline	tetracycline
Third generation cephalosporins	cefdinir	cefotaxime	ceftibuten
	cefditoren	cefepodoxime	ceftriaxone
	cefixime	ceftazidime	
Urinary anti-infectives	fosfomicin	nitrofurantoin macrocrystals-	
	nitrofurantoin	monohydrate	
		trimethoprim	
	nitrofurantoin macrocrystals		

Source: Taken from HEDIS measure(13)

Table A2: Subset of Antibiotics Defined as “Broad Spectrum” for analyses

Description		Prescription	
Beta-lactamase inhibitors	amoxicillin-clavulanate		
Macrolides	azithromycin clarithromycin		
Quinolones	ciprofloxacin	levofloxacin	norfloxacin
	gatifloxacin	lomefloxacin	ofloxacin
	gemifloxacin	moxifloxacin	sparfloxacin
Second generation cephalosporin	cefaclor	cefoxitin	cefuroxime
Third generation cephalosporins	cefotetan	cefprozil	loracarbef
	cefdinir	cefotaxime	ceftibuten
	cefditoren	cefpodoxime	ceftriaxone
	cefixime	ceftazidime	

Table A3: Exclusion Criteria for Secondary Diagnoses Indicating Antibiotic Prescription

Diagnosis Description	ICD-9 Codes	Number Excluded
Nonsuppurative otitis media	381	0
	381.01	3
	381.1	0
	381.2	0
	381.3	0
	381.4	0
Suppurative otitis media	382	149
Acute sinusitis	461	31
Chronic sinusitis	473	119
Acute pharyngitis	462	132
Acute tonsillitis	463	12
Streptococcal sore throat	034.0	7
Pneumonia	481	0
	482	1
	483	0
	484	0
	485	0
	486	15
Bacterial infections	041	5
Urinary tract infections	590	0
	595	0
	597	0
	599.0	7
Acne	706.1	4
Emphysema among adults	492	3
Chronic bronchitis among adults	491	3

Table A4: Single-year GEE models for receipt of antibiotic prescription for acute bronchitis/URI visits

Variable	2006	2007	2008	2009	2010
Provider uses e-warning	0.76	0.97	0.89	0.77	0.70
Provider uses e-prescribing	2.53	1.25	0.83	0.89	1.80
Provider uses EMR	0.52	1.38	1.11	0.94	1.10
Provider specialty:					
Pediatrics	(Reference)	(Reference)	(Reference)	(Reference)	(Reference)
General/family medicine	3.58***	1.78	3.02***	1.58	1.72
Other	3.69**	1.44	1.55	1.52	2.24*
Provider Office Type:					
Private practice	(Reference)	(Reference)	(Reference)	(Reference)	(Reference)
HMO	1.00	0.26	0.48	0.21	0.17*
Other	0.79	0.91	0.74	1.00	0.93
Patient Insurance Type:					
Private	(Reference)	(Reference)	(Reference)	(Reference)	(Reference)
Medicare	1.06	0.66	1.50	0.64	0.85
Medicaid	0.74	0.84	1.18	0.66	0.82
Self-pay	0.92	0.77	2.14	1.44	1.27
Other	0.72	0.97	0.50	1.01	0.67
Patient age:					
0 – 4	0.91	0.70	0.59	0.64	.43**
5 – 17	1.14	0.82	1.40	0.76	0.56
18 – 64	(Reference)	(Reference)	(Reference)	(Reference)	(Reference)
> 65	0.60	1.54	0.51	1.36	0.46
Patient race:					
Non-Hispanic White	(Reference)	(Reference)	(Reference)	(Reference)	(Reference)
Non-Hispanic Black	1.41	0.85	1.33	1.29	1.25
Hispanic	0.69	0.80	0.66	0.94	0.94
Other	0.85	0.60	0.76	0.21**	0.67
Patient chronic condition(s):					
Asthma	1.01	1.27	0.62	0.85	0.69
COPD	2.81***	3.46***	4.24***	1.89**	2.19**
Constant	0.17***	0.37**	0.34**	0.60	0.66

* p < .05

** p < .01

*** p < .001

Table A5: Odds Ratios from GEE model for receipt of antibiotic prescription, with e-warning/yearly interaction term

Variable		Odds Ratio
Provider uses e-warning		0.56*
<i>Interaction Term: E-warning*Proportion of providers using e-warning in survey year</i>		2.30
Provider uses e-prescribing		1.40*
Provider uses EMR		1.03
Provider specialty:	Pediatrics	Reference
	General/family medicine	2.03***
	Other	1.93***
Provider Office Type:	Private practice	Reference
	HMO	0.24**
	Other	0.89
Patient Insurance Type:	Private	Reference
	Medicare	0.96
	Medicaid	0.79*
	Self-pay	1.29
	Other	0.80
Patient age:	0 – 4	0.63***
	5 – 17	0.85
	18 – 64	Reference
	> 65	0.78
Patient race:	Non-Hispanic White	Reference
	Non-Hispanic Black	1.23
	Hispanic	0.81
	Other	0.54***
Patient chronic condition(s):	Asthma	0.87
	COPD	2.71***
Constant		0.41***

* p < .05

** p < .01

*** p < .001

Table A6: Odds Ratios from GEE model for receipt of Broad Spectrum Antibiotic Prescription for visits resulting in any antibiotic prescription

Variable		Odds Ratio
Provider uses e-warning		1.54
Provider uses e-prescribing		0.72
Provider uses EMR		1.03
Provider specialty:	Pediatrics	Reference
	General/family medicine	0.92
	Other	1.39
Provider Office Type:	Private practice	Reference
	HMO	0.50
	Other	0.60*
Patient Insurance Type:	Private	Reference
	Medicare	0.88
	Medicaid	1.03
	Self-pay	1.09
	Other	1.59
Patient age:	0 – 4	1.42
	5 – 17	0.78
	18 – 64	Reference
	> 65	2.03**
Patient race:	Non-Hispanic White	Reference
	Non-Hispanic Black	0.56 *
	Hispanic	0.43***
	Other	0.63
Patient chronic condition(s):	Asthma	0.90
	COPD	1.15
NAMCS Survey Year:	2006	Reference
	2007	1.30
	2008	1.39
	2009	1.28
	2010	1.47
Constant		0.25***

* $p < .05$

** $p < .01$

*** $p < .001$